# LHD Bi-Weekly Call

Jan 11, 2022

## **Opening Remarks & Leadership Update**

Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH Deputy Director/Section Chief						
	Local and Community Support						
Epi Picture	Zack Moore, MD, MPH						
_p	State Epidemiologist and Epidemiology Section Chief						
	- ···· _p······						
Policy	Elizabeth Cuervo Tilson, MD, MPH						
	State Health Director						
	Chief Medical Officer						
Vaccine Update	Ryan Jury, RN, MBA						
vacchie opuale	COVID-19 Vaccine Program Director						
	COVID-19 Vaccine Program Director						
Contact Tracing	Erika Samoff, PHD, MPH						
Contact Tracing	Surveillance Manager NC DHHS						
	Surveillance Manager NC Drin IS						
Testing	Natalie Ivanov, MPH						
	Director of DHHS State-wide COVID testing program and C	COVID vaccination vendor program.					
SLPH	Scott M. Shone, PhD, HCLD(ABB)						
		Laboratory Director					
	•						
Distribution of N95 Masks	Charlene Wong ,MD, MSHP	David Ezzell					
	Chief Health Policy Officer for COVID-19 at NC DHHS	EMS Education Consultant					
Infection Prevention Update	Emily Berns, MPH, RN						
		Nurse Consultant: Division of Public Health, Communicable Disease Branch					
	NC Department of Health and Human Services						
Waste Water Surveillance							
TTASLE TTALET SULVEINANCE		Ariel Christensen, MPH Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch					
	Division of Public Health NC DHHS						
NA 6C DEPARTMENT OF							
HEALTH AND HUMAN SERVICES	QUESTIONS?						
	function or email your questions to: questionsCOVID19webinar@gr						

2


## **Epi Picture**

Opening Remarks & Leadership Undete	Both Lovotto, DN, DSN, MDH
Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH Deputy Director/Section Chief
	Local and Community Support
	,
Epi Picture	Zack Moore, MD, MPH
	State Epidemiologist and Epidemiology Section Chief
Policy	Elizabeth Cuervo Tilson, MD, MPH
	State Health Director
	Chief Medical Officer
Vaccine Update	Ryan Jury, RN, MBA
	COVID-19 Vaccine Program Director
Contact Tracing	Erika Samoff, PHD, MPH
	Surveillance Manager NC DHHS
Testing	Natalie Ivanov, MPH
	Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.
SLPH	Scott M. Shone, PhD, HCLD(ABB)
	Laboratory Director
Distribution of N95 Masks	Charlene Wong ,MD, MSHP David Ezzell
	Chief Health Policy Officer for COVID-19 at NC DHHS EMS Education Consultant
Infection Prevention Update	Emily Berns, MPH, RN
·	Nurse Consultant: Division of Public Health, Communicable Disease Branch
	NC Department of Health and Human Services
Waste Water Surveillance	Ariel Christensen, MPH
	Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch
	Division of Public Health NC DHHS
THE ALT H AND HUMAN SERVICES	QUESTIONS?
Place use the Zeem Of	A function or email your questions to: questionsCOVID19webinar@gmail.com

3



NC DEPARTMENT OF HEALTH AND HUMAN SERVICES



# **Update on COVID-19 Trends**


January 11, 2022



# **Case Rates Continue to Increase for All Age Groups**

Case Rates


Case rates are highest among young adults (ages 18-24) and lowest among older populations (ages 65+), potentially due to higher vaccination rates and booster rates among older adults.



# **Highest Test Positivity Recorded Across All Age Groups**

Case Rates


Percent positivity has increased rapidly since mid-December, with percent positivity now exceeding 25% in most age groups (except older adults).



## **Case Rates Among Children Surpass Previous Peaks**




Case rates are increasing across all age groups – including young children. This trend was not observed with the Delta variant.



# **Racial Disparities Continue to Grow**




Case rates among Black/African American population have increased disproportionately compared to other races. This is potentially due to multiple factors, including lower booster coverage and increased exposure risks.



# **Ethnic Disparities Continue to Widen**




#### Case rates among the Hispanic population are ~1.5x higher than rates among the non-Hispanic population.



## **2021-22 COVID-Like Illness ED Visits at Record Highs**






# **Omicron Case Rates Now Declining in South Africa and UK**

Early evidence suggests that the Omicron surge has already peaked in South Africa and the UK, two countries that were earliest affected by the new variant.

**Omicron Variant** 




Source: <u>Financial Times analysis</u> of data from Johns Hopkins CSSE, World Health Organization, and UK Government coronavirus dashboard

# **Omicron Also May Have Peaked in Some US Cities**

COVID-19 cases in New York and the District of Columbia appear to have begun to plateau.

**Omicron Variant** 



Source: <u>Financial Times analysis</u> of data from Johns Hopkins CSSE, World Health Organization, and UK Government coronavirus dashboard

## Policy

Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH Deputy Director/Section Chief Local and Community Support		
Epi Picture	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief		
Policy	Elizabeth Cuervo Tilson, MD, MPH State Health Director Chief Medical Officer		
Vaccine Update	<b>Ryan Jury, RN, MBA</b> COVID-19 Vaccine Program Director		
Contact Tracing	Erika Samoff, PHD, MPH Surveillance Manager NC DHHS		
Testing	<b>Natalie Ivanov, MPH</b> Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.		
SLPH	Scott M. Shone, PhD, HCLD(ABB) Laboratory Director		
Distribution of N95 Masks	Charlene Wong ,MD, MSHPDavid EzzellChief Health Policy Officer for COVID-19 at NC DHHSEMS Education Consultant		
Infection Prevention Update	<b>Emily Berns, MPH, RN</b> Nurse Consultant: Division of Public Health, Communicable Disease Branch NC Department of Health and Human Services		
Waste Water Surveillance       Ariel Christensen, MPH         Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch         Division of Public Health NC DHHS			
Please use the Zoom Q&A	QUESTIONS? A function or email your questions to: questionsCOVID19webinar@gmail.com		

13

## Vaccine Update

Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH
	Deputy Director/Section Chief
	Local and Community Support
Epi Picture	Zack Moore, MD, MPH
	State Epidemiologist and Epidemiology Section Chief
Policy	Elizabeth Cuervo Tilson, MD, MPH
	State Health Director
	Chief Medical Officer
Vaccine Update	Ryan Jury, RN, MBA
	COVID-19 Vaccine Program Director
Contact Tracing	Erika Samoff, PHD, MPH
	Surveillance Manager NC DHHS
Testing	Natalie Ivanov, MPH
	Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.
SLPH	Scott M. Shone, PhD, HCLD(ABB)
	Laboratory Director
Distribution of N95 Masks	Charlene Wong ,MD, MSHP David Ezzell
	Chief Health Policy Officer for COVID-19 at NC DHHS EMS Education Consultant
nfection Prevention Update	Emily Berns, MPH, RN
	Nurse Consultant: Division of Public Health, Communicable Disease Branch NC Department of Health and Human Services
Waste Water Surveillance	Ariel Christensen, MPH
	Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch Division of Public Health NC DHHS
THE DEPARTMENT OF	QUESTIONS?
Please use the Zoom	Q&A function or email your questions to: questionsCOVID19webinar@gmail.com

# NCDHHS COVID-19 Vaccine LHD Update

January 11, 2022





#### NC DHHS COVID-19 Response

# Vaccines EUA and CDC Recommendation Status



#### FDA, CDC EXPAND RECOMMENDATIONS FOR PFIZER AND MODERNA VACCINE

#### The FDA and CDC have expanded their recommendations for:

#### **Pfizer:**

- Expand the use of a single Pfizer-BioNTech booster dose to include use in individuals 12 through 15 years of age.
- Shorten the time recommended between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 vaccine and use of a booster dose to five months.
- Allow for a third Pfizer-BioNTech primary series dose for certain immunocompromised children 5 through 11 years of age. Please note: Only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for children ages 5-11.

#### Moderna:

• Shorten the time recommended between the completion of primary vaccination of the Moderna COVID-19 vaccine use of a booster dose to five months.

#### Please reference the updated **Pfizer-BioNTech EUA** and **Moderna EUA** fact sheets.

#### DHHS Actions

- All standing orders have been updated and executed
- Press release and provider communications have been sent out



#### IMMUNOCOMPROMISED INDIVIDUALS NOW ELIGIBLE FOR FOUR DOSES



#### Update:

- **Some** moderately or severely immunocompromised people who received THREE (3) doses of the Pfizer-BioTech or Moderna primary series may now be eligible for a booster dose.
- Everyone 12 years and older, including immunocompromised people, should get a booster shot. If you are eligible for an additional primary shot, you should complete all three doses first before you get a booster shot.

#### **Connecting the dots:**

- shot) perio
- According to recently released recommendations by the CDC, some immunocompromised individuals can get what would amount to a fourth dose (booster shot) of the COVID-19 vaccine as early as this coming week due to the shortened wait period of 5 months.
  - This dose would be a booster dose of the Pfizer/Moderna vaccine, beyond the third additional dose that was originally authorized for immunocompromised individuals in August of 2021
  - This does NOT apply to individuals who received a Johnson & Johnson primary vaccine



#### **FDA COVID-19 VACCINE BOOSTER QUALIFICATION**

Which primary vaccine series did you complete?	Pfizer-BioNTech	Moderna	Janssen (J&J)	
You should get a booster if:	It's been at least 5 months since completing the primary series AND you are:	It's been at least 5 months since completing the primary series AND you are:	It's been at least 2 months since completing the primary series AND you are:	
	Age 12+	Age 18+	Age 18+	
If eligible, you can get a booster of:	<ul> <li>✓ Pfizer BioNTech*</li> <li>✓ Moderna</li> <li>✓ Janssen (J&amp;J)</li> <li>*Only Pfizer-BioNTech can be used as a booster in those age 12-17</li> </ul>	<ul> <li>✓ Moderna</li> <li>✓ Pfizer BioNTech</li> <li>✓ Janssen (J&amp;J)</li> </ul>	<ul> <li>✓ Janssen (J&amp;J)</li> <li>✓ Pfizer BioNTech</li> <li>✓ Moderna</li> </ul>	
If eligible for a booster shot according to the guidelines above: A fourth dose is available for:	Booster qualified people age 5+ who are <b>moderately or</b> <b>severely</b> <b>immunocompromised</b> and have received an additional third dose	Booster qualified people age 18+ who are <b>moderately or</b> <b>severely immunocompromised</b> and have received an additional third dose	No additional primary dose has been authorized at this time, therefore a fourth dose is not applicable for this brand	



# Moving Away from "Fully Vaccinated"



#### MOVING AWAY FROM "FULLY VACCINATED"

Given current guidance, NCDHHS plans to shift from the phrase "Fully Vaccinated" to a phrase that helps people understand there may continue to be an updated schedule for COVID-19 boosters. Like other vaccines, we need people to get boosted according to the recommended schedule.

**Recommendation:** Use "current" or "up-to-date" instead of "fully vaccinated." *Example*: The best way to protect yourself from hospitalization and death is to stay up-to-date on your COVID-19 vaccines.

#### **Dashboard Changes Planned for 1/14:**


- Transition metric name from "Fully Vaccinated" to "Vaccinated with 2 Doses or One 1 Dose J&J".
- Add state-level and county metrics on people that are vaccinated with at least one booster/additional dose (see dashboard drafts below):
  - State-level metrics on the percent of the vaccinated population that has received at least one booster/additional dose will be added to the "Summary Data" tab of the <u>Vaccinations dashboard</u>
  - County-level data on total booster/additional doses administered will be made available on the county map section of the "Summary Data" tab of the <u>Vaccinations dashboard</u>



#### VACCINATIONS DASHBOARD ADDITIONS

- Planned dashboard release:
  - 1/14:
    - Transition metric name from "Fully Vaccinated" to "Vaccinated with Two Doses or One Dose J&J"
    - Add state-level and county metrics on people that are vaccinated with at least one booster/additional dose
- Communications: NCDHHS will share a press release when the dashboard is posted with the additions

#### Updated Fully Vaccinated metric name & new metrics on boosters



Updated Fully Vaccinated metric name & county-level data on boosters

Select Population

Total Populatio


36,328

Total Population


Alamance Count

Select County:

Alamance County



#### **VACCINATIONS DASHBOARD ADDITIONS**



12+ Years

18+ Years


65+ Years

Total

5+ Years

#### **VACCINATIONS DASHBOARD ADDITIONS**

#### Updated Fully Vaccinated metric name & county-level data on boosters






# Pediatric & Booster Vaccination Data Update




#### **PEDIATRIC VACCINATION RATES**



Source: All metrics are from 1/06/22 ASPR Report Note: FEMA IV states shown are states with comparable vaccine programs.

The pace of pediatric vaccination rates lags slightly behind the pace of adolescent rates


Day 1 is regarded as first day CDC deemed each age group eligible for COVID vaccination.



Note: Day 1 is May 12, 2021 for adolescents and November 3, 2021 for pediatrics. Dose 1 Only, Data through 1/4/2021



#### **BOOSTER ADMIN TRENDS BY BRAND AND RACE VARY WEEK OVER WEEK**



Booster doses include individuals 12+

# **SNF Update**



#### **NC BOOSTER VACCINATION ANALYSIS AND BENCHMARKING AS OF 1/4**



Need to explore other operational levers to address remaining unpartnered facilities

Non-SNF Booster Vaccinations (# of Facilities with a Provider partner or in Need of Partnership)


~60% of Non-SNF's have been partnered with a vaccine provider. Below represents the distribution of partnered facilities and facilities without a partner

Campaign Total						
3551	2164	1	<b>1387 81%</b>			
Total # of facilities	Total Facilities w/ confirmed provider*		lities without ovider	Percent of beds covered		
	Awaiting Vendor Supp	ort	No Con	firmed Partner		
	157		104	1126		
	Currently scheduled or awai vendor support	ting	Declined par	tner Facilities unable to reach		
	~2% of bed count		~2% of bec count	d ~16% of bed count		

**SNF Booster Rates of Vaccination** 

(For staff & residents as of 12/19/2021)

NC rates of vaccination for both staff and residents in North Carolina either match or are closely on par with Nationwide rates



■Nationwide ■NC ■Region IV

	Nationwide	NC	Region IV
# of Residents who have Received Booster Vaccination	406,673	12,271	69,882
# of Healthcare Personnel who have Received Booster Vaccination	255,277	6,753	37,775

64% of overall NC population 65+ years old have received a booster vaccination as of 1/05/21 (State and Tiberius reports)



#### PHARMACY RECIPIENT RECORDS ARE CONVERTED TO REGULAR CVMS RECIPIENT RECORDS

CVMS Provider Portal		
Home Recipient Appointments Locations Bulk Registration Vaccine Inventory Vaccine Marketplace Shipments	More V	
Hint: For quicker and more relevant search results, enter full name (ex. John Smith) or email address and date of birth.       Create         Q. Full name, ex: John Smith       Q. Email, John@j.com       Date of Birth (optional), MM/DD/YYYY	WR Recipient         Image: CMAS Provider Portal	8
Search	Home Recipient Appointments Locations Bulk Registration Vaccine Inventory Vaccine Marketplace Shipments           Person Account         Schedule First Dose Appointment         Schedule Second Dose	More 🗸
Recipients within CVMS         0 records found         First Name       Middle Name       Last Name       Date of Birth       Gender       Vaccine Pro       Recipient Do       Date of Adm       Email       V       I	Birthdate Gender Mobile Email Recipient Dose Status 3/17/1987 Male Dose 1 Administered	Page 1 of 1
Recipients from Long Term Care/Federal Pharmacy.	Details       Related         You can view the full details of each vaccine administration by clicking on a single Vaccination Log Name hyperlink or click: "View AII" for all history.         U       Vaccination Logs (1)	North Carolina COVID-19 Vaccination Information
First Name v Last Name v Date of Birth Vaccine Manufacture v Vaccination Vaccine Manufacture v Vaccine Manufacture v Vaccination Vaccine Manufacture v	Vectoriation Cogs (1)      VL-000082349      Date and Time of Vaccination: 12/7/2021.11.31 AM     Vaccine: Phere BiolNete 12e9 (6 doses/vial) (25 MDV) COVID-19 Vaccine      Phere BiolNete 12e9 (6 doses/vial) (25 MDV) COVID-19 Vaccine	Daffy B Duck104 Date of Birth: 09/15/1999 Vaccination Information PDF Generated: 01/07/2022
	View All	COVID-19 Immunization History Date Dose Number / Vaccine Product / Lot Number Administered by Manufacturer
	Contact Information Email Mobile	10/13/2021         1 of 2         Pffizer-BioNitech         LotPfil12221PS         Defnall Planmacy Recipient Conversion Location           10/13/2021         2 of 2         Pffizer-BioNitech         LotPfil12221PS         Defnall Planmacy Recipient Conversion Location
	Address 1     Home Phone       1234 Main Ave	01/05/2022 Pfize-BioNtech Test:456 DoNotUse-NotPealLoc-Cathy093021 Administering Provider(s) Scan the QR Code provided below
	North Carolina Brumwick Brumwi	Dose 1 of 2 Pfizer-BioNtech Default Pharmacy Recipient Conversion Location
		Prote Number
		Pfizer-BioNech DoNotUse-NotRealLoc-Cathy093021 123 Main St. Vik, Iceland, North Carolina 99999 Phone Number: 555-5555
NC DEPARTMENT OF HEALTH AND HUMAN SERVICES		COVID-19 vaccine information contained within this document was generated from the NC COVID-19 Vaccine Management System (CVMS). This document contains confidential health information and is intended for the vaccine recipient's use only.

# Therapeutics & Treatment



<u>Monoclonal antibodies</u>, or mAbs, are antibodies made in a laboratory to fight a particular infection. The Food and Drug Administration (FDA) has issued **Emergency Use Authorization (EUA)** for the use of monoclonal antibody therapies for adult and pediatric patients aged 12 and older (bam/ete authorized for all ages). mAbs are given to patients with an infusion, subcutaneous injection, or intramuscular injection. They are used for treatment or prevention. There are four types of mAbs that have been authorized for use for COVID-19:

mAbs Generic Name	Also known as	Authorized Indication	Route of Administration	Dosing Regimen	Authorized Patient Population	Standing Order?	Variant Efficacy	Allocation Estimates
Casirivimab / imdevimab	REGEN- COV	Post-exposure Prophylaxis, Treatment within 10 days of symptoms	Subcutaneous Injection; Intravenous Infusion	600 mg of both	Patients aged 12 years and older	Yes, revised January 5th	Reduced efficacy against Omicron	~1,000 per week
Bamlanivimab / etesevimab	Bam/Ete	Post-exposure Prophylaxis, Treatment within 10 days of symptoms	Intravenous Infusion	Dosage varies with weight	Patients of all ages, including neonates	Yes, revised January 5th	Reduced efficacy against Omicron*	~1,000 per week
Sotrovimab	Sotrovimab	COVID-19 Treatment within 10 days of symptoms	Intravenous Infusion	500 mg of Sotrovimab	Patients aged 12 years and older	Yes, revised January 5th	Retained efficacy against Omicron*	~1,000 per week
Tixagevimab / cilgavimab	Evusheld AZD7442	Pre-exposure prophylaxis (PrEP)	Intramuscular Injection	Two simultaneous IM injections every 6 months	Patients aged 12 years and older who are immunocompromised or have a contraindication for COVID-19 vaccines	No – per FDA/HHS.	Retained efficacy against Omicron	~2,000 per week



\*Bam/Ete and Sotrovimab data is preliminary, have not published official studies yet regarding efficacy

#### **ORAL ANTIVIRAL - OVERVIEW**

Two investigational COVID-19 oral antiviral therapies are expected to gain EUA over the next month. Both therapeutics target mild-to-moderate COVID-19 for adults who are at risk of severe illness:

Generic Name	Also known as	Authorized Indication	Route of Administration	Standing Order	Administration Requirements	Dosing Regimen	Authorized Patient Population	Variant Efficacy	Allocation Estimates
Molnupiravir	MK- 4482, Merck	Treatment of mild- to-moderate COVID- 19 in adults who are at risk for progressing to severe COVID-19 and for whom alternate treatment is not accessible or clinically appropriate	Oral	No per FDA/HHS	Must start within 5 days of symptom onset Not recommended during pregnancy	800 mg twice-daily for five days	Adult (18+)	30% effective in preventing hospitalizations or deaths within 5 days of symptom onset. Expected to maintain effectiven ess across all variants.	~10,000 per two-week cycle
Paxlovid	Nirmatr elvir / Ritona vir, Pfizer	Treatment of mild- to-moderate COVID- 19 in adults and pediatrics (12+) who are at risk for progressing to severe COVID-19	Oral	No per FDA/HHS	Must start within 5 days of symptom onset Dosage adjustment for moderate renal impairment Drug interactions list	300mg of nirmatrelvi r and 100 mg of ritonavir twice-daily for five days	Adult and Pediatric (12+)	88% effective in preventing hospitalizations or deaths within 5 days of symptom onset. Expected to maintain effectiven ess across all variants.	~2,500 per two-week cycle



#### **NEW PROVIDER GUIDANCE & UPDATED SWSO**

#### **Patient Prioritization**

Due to the limited supply of COVID-19 therapeutics and the emergence of the Omicron variant, the NIH Panel has arranged tiers of patient prioritization. North Carolina's Standing Order prioritizes treatment for patients in Tier 1 & Tier 2:

Tier 1	Immunocompromised individuals not expected to
	mount an adequate immune response to COVID-19
	vaccination or SARS-CoV-2 infection due to their
	underlying conditions, regardless of vaccine status
	(see Immunocompromising Conditions below); or
	Unvaccinated individuals at the highest risk of severe
	disease (anyone aged ≥75 years or anyone aged ≥65

Tier 2	Unvaccinated individuals at risk of severe disease not
	included in Tier 1 (anyone aged ≥65 years or anyone
	aged <65 years with clinical risk factors)

years with additional risk factors).

#### **Drug Prioritization**

Due some treatment's reduced susceptibility to the emerging Omicron variant, North Carolina is following the NIH's recommendations to use the following therapeutics (listed in order of preference):

1.	Paxlovid (Pfizer)
2.	Sotrovimab
3.	Remdesivir*
4.	Molnupiravir (Merck)

REGEN-COV and BAM/ETE are unlikely to retain activity against the Omicron variant. Providers can only allocate these if: 1) they have capability to identify a potential case of the Omicron variant **AND** can administer that product within 48 hours, or 2) local indicators point to Omicron not being the predominant variant

\*Remdesivir is not currently allocated by NC DHHS

**Statewide Standing Order:** The Standing Order has been revised to provider patient prioritization criteria in the *Specific Assessment* Criteria with the criteria mentioned in Tiers 1 & 2. North Carolina's also updated the Standing Order for BAM/ETE and REGEN-COV (SQ and IV) stating that these can only be administered as a treatment where providers can rule out the Omicron variant.



#### **ENROLLMENT & RECIPIENT WAYFINDING**


Enrollment:

NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

- <u>New Provider Enrollment Form</u>
- Targeted Outreach
  - Dispensing Physicians
  - NCCHCA
- HRSA Direct Federal Allocation Program
  - Piedmont, Triad Adult and Pediatric Medicine, Rural Health Group and Greene County Health Care

Wayfinding Improvements:

- The <u>'Find COVID-19 Treatment'</u> section on the NC DHHS website includes an updated 'Site Finder' tool that enables recipients to:
  - Search for nearby treatment sites
  - Discover available treatments each site offers for administration
  - Find resources to schedule an appointment (phone numbers, websites)
- The '<u>Information For Individuals at Higher Risk</u>' section on the NC DHHS website includes a 'Site Finder' tool specifically for EVUSHELD treatment locations.



#### Subscribe to our NC DHHS COVID-19 Therapeutics listserv

#### Site Finder Tool on NC DHHS Website


## **Contact Tracing**

Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH Deputy Director/Section Chief
	Local and Community Support
Epi Picture	Zack Moore, MD, MPH
	State Epidemiologist and Epidemiology Section Chief
Policy	Elizabeth Cuervo Tilson, MD, MPH
	State Health Director Chief Medical Officer
Vaccine Update	Ryan Jury, RN, MBA
	COVID-19 Vaccine Program Director
Contact Tracing	Erika Samoff, PHD, MPH
	Surveillance Manager NC DHHS
Testing	Natalie Ivanov, MPH
	Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.
SLPH	Scott M. Shone, PhD, HCLD(ABB)
	Laboratory Director
Distribution of N95 Masks	Charlene Wong ,MD, MSHP David Ezzell
	Chief Health Policy Officer for COVID-19 at NC DHHS EMS Education Consultant
Infection Prevention Update	Emily Berns, MPH, RN
	Nurse Consultant: Division of Public Health, Communicable Disease Branch NC Department of Health and Human Services
Waste Water Surveillance	Ariel Christensen, MPH Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch
	Division of Public Health NC DHHS
AC DEPARTMENT OF HEALTH AND HUMAN SERVICES	QUESTIONS?
Please use the	Zoom Q&A function or email your questions to: questionsCOVID19webinar@gmail.com

38

## CI/CT for LHDs

Erika Samoff NC DPH Contact Tracing January 11, 2022





## **REVISED CASE INVESTIGATION/CONTACT TRACING GUIDANCE**

### Why Now

- We need sustainability
- Technological tools are available

## **Revised CI/CT Plan, Effective Immediately**

- Digital outreach to *all case patients* continues through texts and emails
  - Call center remains available
- Case investigation and telephone outreach *recommended for case patients reported to be in high-priority settings*
- Case investigation and contact tracing no longer recommended for general public
- When you can, info and resource calls (case investigation/contact tracing not recommended) to:
  - General public whose text is not delivered
  - People in underserved communities as defined locally

### **Planning Process**

Meeting	Attendees
Initial Planning and	<ul> <li>LHD Directors</li> <li>NC DPH CDB Leadership</li> <li>Contact Tracing Strategy</li></ul>
Listening Session	Team
Listening Sessions	<ul><li>DHHS HMP Team</li><li>CI/CTs</li><li>CD Nurses</li></ul>
Review Findings and	<ul> <li>LHD Directors</li> <li>NC DPH CDB Leadership</li> <li>Contact Tracing Strategy</li></ul>
Develop Strategy	Team

### **REVISED CASE INVESTIGATION/CONTACT TRACING GUIDANCE**

### Please see the prioritization guidance memo on the CD Manual.

	Revised Priority Level Definitions for Case Investigation		
Priority	Time from specimen collection to case review	Population	Action
1	Any ('last in, first out')	<ul> <li>Cases reported to be linked to a cluster/outbreak</li> <li>Individuals reported to the local health department with known epidemiologic links to a cluster, outbreak or location or event associated with two or more cases</li> <li>Cases known reported as living in a congregate or healthcare setting</li> <li>Individuals reported to the local health department as residing in a congregate living setting (e.g., correctional facilities, homeless shelters, migrant farm worker housing, skilled nursing, mental health and long-term care facilities)</li> </ul>	Case investigation and contact tracing
2	Up to 5 days ('last in, first out')	<ul> <li>Cases known to be working or potentially exposed in a high-density setting</li> <li>Healthcare settings (e.g., acute care, skilled nursing, mental health and long-term care facilities)</li> <li>Congregate settings (e.g., correctional facilities, homeless shelters, migrant farm worker camps)</li> <li>K12 Schools</li> <li>Critical infrastructure work settings (e.g., food processing plants, manufacturing plants, transportation, food service to critical workers, childcare, first responders)</li> <li>Community settings with large numbers of people (e.g., mass gatherings, religious events). Indoor settings should be prioritized over outdoor settings.</li> </ul>	Case investigation and contact tracing
3	Up to 5 days ('last in, first out')	Case patients whose CCTO record indicates their text was not delivered	Notification phone call to provide isolation instructions and links to
4	Up to 10 days ('last in, first out')	<b>Case patients in populations most likely to have resource needs</b> ; populations can be defined by geography (zip or address), race/ethnicity, age according to local needs.	investigation interview no contact tracing

### **REVISED CASE INVESTIGATION/CONTACT TRACING GUIDANCE**

### **Staffing Considerations**



### Flexing existing staff

CCTC staff can be flexed to cover vaccination, testing, CI/CT, and data entry needs. Vaccination is still our most important tool to reduce the size of case surges and should be first priority.



### Leveraging CCTC clinical staff & vaccination support staff

Requests for CCTC clinical staff (who can support the administration of both vaccines and tests) and vaccination and testing support staff can be placed through ServiceNow.

### Maintaining current CI/CT staffing levels

0		Q		0	
	ĺ		Ĵ		)


- While particular situations will be considered, we do not plan to increase case investigation and contact tracing staff beyond current levels during this case surge
- Vaccine support and clinical staff hiring will be unaffected.



### **Q/I GUIDANCE UPDATES- CASE AND CONTACT NOTIFICATION CHANGES**

Emails, texts, and portal landing page language have been updated per the following based on the recent change to Q/Iguidance:

- Updated the calculated guarantine/isolation end date to be 5 days post exposure or onset of illness
- Clarified criteria to end ٠ quarantine/isolation
- Added instruction for strict mask use after quarantine/isolation
- **Clarified when to get a test** ٠
- Updated guarantine exemption rules to ٠ match CDC



#### **NCDHHS**

#### Home | Q, | English - | Sign in

#### Help slow the spread of COVID-19!

You have received a message from the NC COVID Community Team because you recently tested positive for COVID-19. The NC COVID Community Team is here to help you get the resources, information, and support you need to protect yourself and your family. You may also receive a phone call from the NC COVID Community Team at 844-628-7223. If you see us calling please answer the call!

Our records show you tested positive for COVID-19 on:

12/30/2021

Please e

I have n

Based o

02/05/2

#### Since you tested positive, you should isolate yourself from others to protect yourself and your loved

ones. Isolation means that you should stay home and avoid sharing a bedroom, bathroom, or common spaces with anyone else in your household. You should isolate through at least the date below. If you have symptoms, continue to isolate until your symptoms are resolving. For more information on how to properly isolate, please refer to this CDC webpage.

You should also wear a mask around others for an additional 5 days after your end of isolation date.

ease enter the date you My COVID-19 symptoms began on	8 NCDHHS	Home   Q,   English -	Sign ir
1/31/2022	Help slow the spread of COVID-19!		
I have not had any COVID-19 sympt	You have received a message from the NC COVID Community Team because someone with COVID-19. The NC COVID Community Team is here to help yo support you need to protect yourself and your family. You may also receive.	ou get the resources, information,	
ased on your testing date	Community Team at 844-628-7223. If you see us calling please answer the c		
2/05/2022 and wear a ma	Based on the date you were exposed, it is recommended that you quarantin from others) through at least the date below (which is based on a quarantin you were exposed to COVID-19). If symptoms occur, you should quarantine symptoms are not attributable to COVID-19. For information on how to prop CDC webpage.	ne period of 5 days from the last da until a negative test confirms	ate
	You should quarantine through at least:		
	1/5/2022		
	It is also recommended that you get a COVID-19 test on the date listed abor finding a testing place, can be found here. If you test positive, you should is		
	If you are not experiencing symptoms after the date above, you may leave h others for an additional 5 days.	nome while wearing a mask aroun	nd
	You may qualify for an exemption from quarantine if you meet one of the fo	ollowing criteria:	
	<ul> <li>Have had a COVID-19 vaccine booster shot</li> <li>Completed the primary series of Pfizer or Moderna COVID-19 vaccine w</li> <li>Completed the primary series of J&amp;J COVID-19 vaccine within the last 2</li> </ul>		
	Even if exempt from quarantine, you should still wear a mask around others period (the date listed above) and for an additional 5 days beyond that date	through the recommended quara	antine



### **CONTACT TRACING RESOURCES**

	COVID-19 Community Team O	streach Tool 🕰
<section-header><section-header><text></text></section-header></section-header>		· · ·
The runner of t		
	opeans repacting	Lottact nontration
	cented, miditation have now learn system to include a status phase automatic to the center phase motion as well of included as well and the status of the encluded as and the status of the status of the term testing positive in the part time motion of the status of the	<ul> <li>Insertion of the sector of the</li></ul>

**CCTO** Job Aids

## CCTO job aids include information on

- <u>digital notification</u>,
- <u>monitoring</u>,
- <u>navigating CCTO</u>,
- <u>technical support</u>,
- ...and more!

Notification
Samples

	See below for relevant job aids.	
Di	gital Exposure Notification - Corr	lacts
Public Health Motifica	for mut	0.2
M Summerly has re-serve	analygen o pr	
No. For New		
The letter N. Court Connecting The 2012 AND sector better in a rest	es. Nuclear lane report la Casta III, and stocki paraeties (sig hore a ca 2015, MAS	Capacity purchases about the super-
the To BEEK, ON YE Is an	with a schedup second and a posts interaction by you but held	And a second second second second
x MC One Contractly least number deadly NC Devid CONE Name		
	C C C C C C C C C C C C C C C C C C C	

The <u>Digital Outreach</u> <u>Samples</u> doc on the CD Manual contains sample texts, emails, and portal screens for contact and case notification.



Case investigation and contact tracing scripts can be found on the <u>Sample Interview Scripts</u> section of the CD Manual.





## Testing

Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH
	Deputy Director/Section Chief
	Local and Community Support
Epi Picture	Zack Moore, MD, MPH
	State Epidemiologist and Epidemiology Section Chief
Policy	Elizabeth Cuervo Tilson, MD, MPH
•	State Health Director
	Chief Medical Officer
Vaccine Update	Ryan Jury, RN, MBA
·	COVID-19 Vaccine Program Director
Contact Tracing	Erika Samoff, PHD, MPH
5	Surveillance Manager NC DHHS
Testing	Natalie Ivanov, MPH
-	Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.
SLPH	Scott M. Shone, PhD, HCLD(ABB)
	Laboratory Director
Distribution of N95 Masks	Charlene Wong ,MD, MSHP David Ezzell
	Chief Health Policy Officer for COVID-19 at NC DHHS EMS Education Consultant
Infection Prevention Update	Emily Berns, MPH, RN
	Nurse Consultant: Division of Public Health, Communicable Disease Branch
	NC Department of Lealth and Llyman Convises
	NC Department of Health and Human Services
Waste Water Surveillance	Ariel Christensen, MPH
Waste Water Surveillance	
Naste Water Surveillance	Ariel Christensen, MPH
	Ariel Christensen, MPH Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch Division of Public Health NC DHHS
HEALTH AND HUMAN SERVICES	Ariel Christensen, MPH Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch

# NC DHHS COVID-19 Prevention & Response LHD Discussion

January 11, 2021





NC DHHS COVID-19 Response

# Current testing support

Vendor	<ul> <li>Vendors available to all LHDs to support one-time and ongoing testing events. Submit requests via the <u>event</u> <u>request form</u></li> <li>Onboarding 2 additional vendors – MAKO and Radeas – for a total of 14 vendors. (See appendix for more details)</li> </ul>	
Staffing	<ul> <li>Available upon request to support various testing-related support</li> <li>Request support via your regional supervisor</li> </ul>	
Federal	<ul> <li>NCDHHS exploring federal support options in the following areas for mass testing events:</li> <li>Registration system</li> <li>Medical personnel</li> <li>PCR tests</li> <li>Specimen processing</li> <li>Result notification</li> </ul>	
<ul> <li>All available for request via <u>online form</u>. Orders are fulfilled as supplies become available. Email on Tuesday confirm ordering for the week.</li> <li>Point-of-Care Tests: All inventory allocated for distribution         <ul> <li>~61,000 tests received yesterday, shipping today to LHDs, K12, and other high-priority facilities.</li> <li>Anticipating receiving an additional 20,000 tests today, for distribution tomorrow</li> <li>Purchase orders for additional ~700k tests awaiting shipment from suppliers for both point-of-care and athome, anticipated in late January/early February</li> </ul> </li> <li>At-home Tests: All inventory allocated for distribution         <ul> <li>Anticipate receiving 105k tests to be used for at-home AND point-of-care by Friday, Jan 14<sup>th</sup></li> <li>Bulk testing supplies: 2.5M NP swabs, 2.9M VTM media             <ul> <li>Ample swabs and media available for request</li> <li>Specimen collection devices: High inventory             <li>Fulfilled and processed by SLPH. Full requirements available on NCDHHS website</li> </li></ul> </li> </ul></li></ul>		

# Additional Information on Supplies

Supplies		
1	Please only request the supplies that you need for the next 1-2 weeks, to allow our team to get tests to all who need immediate supplies.	
2	Our team will contact you with an updated status when available. Emails will come from <u>COVIDCommandCenter@dhhs.nc.gov</u> .	
3	If you have submitted an order and have not received supplies, please do not resubmit your order unless instructed to do so by our team.	
4	NCDHHS is diversifying its supply chain for antigen tests. You may not receive the exact test brand requested (e.g. BinaxNOW, BD Veritor). Details on updating your CLIA accordingly will be shared via email today or tomorrow.	

Vendor	Contracted County Coverage	
МАКО		
Radeas		
Ottendorf	All Counting	
<b>Resourceful Clinical Labs</b>	All Counties	
NCCHCA		
Optum		
Old North State Medical Society	All Counties; Providers based in a few counties, but they have statewide reach	
Cone	5 counties: Alamance, Caswell, Randolph, Guilford, Rockingham	
WakeMed	1 County: Wake	
UPOH	<b>15 Counties</b> : Alamance, Bertie, Cabarrus, Duplin, Durham, Forsyth, Franklin, Hertford, Johnston, Lee, Mecklenburg, Person, Pitt, Rowan, Wake	
Vidant	<b>18 counties:</b> Beaufort, Bertie, Chowan, Dare, Duplin, Edgecombe, Gates, Greene, Halifax, Hertford, Hyde, Lenoir, Martin, Northampton, Pitt, Tyrrell, Washington, Wilson	
StarMed	<b>21 counties:</b> Anson, Buncombe, Cabarrus, Catawba, Chatham, Cleveland, Columbus, Cumberland, Forsyth, Guilford, Haywood, Iredell, Lee, Lenoir, Mecklenburg, Onslow, Orange, Randolph, Swain, Union, Wake	
Wake Forest		
Atrium	Not actively testing outside of clinics	

Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH
	Deputy Director/Section Chief
	Local and Community Support
Epi Picture	Zack Moore, MD, MPH
	State Epidemiologist and Epidemiology Section Chief
Policy	Elizabeth Cuervo Tilson, MD, MPH
	State Health Director
	Chief Medical Officer
Vaccine Update	Ryan Jury, RN, MBA
	COVID-19 Vaccine Program Director
Contact Tracing	Erika Samoff, PHD, MPH
	Surveillance Manager NC DHHS
Testing	Natalie Ivanov, MPH
	Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.
SLPH	Scott M. Shone, PhD, HCLD(ABB)
	Laboratory Director
Distribution of N95 Masks	Charlene Wong ,MD, MSHP David Ezzell
	Chief Health Policy Officer for COVID-19 at NC DHHS EMS Education Consultant
Infection Prevention Update	Emily Berns, MPH, RN
•	Nurse Consultant: Division of Public Health, Communicable Disease Branch
	NC Department of Health and Human Services
Waste Water Surveillance	Ariel Christensen, MPH
	Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch Division of Public Health NC DHHS
NC DEPARTMENT OF	QUESTIONS?
Please use the Zoom Q&A	function or email your questions to: questionsCOVID19webinar@gmail.com

## **Distribution of N95 Masks**

Opening Remarks & Leadership Update	Beth Lovette, RN, BSN, MPH
	Deputy Director/Section Chief
	Local and Community Support
Epi Picture	Zack Moore, MD, MPH
	State Epidemiologist and Epidemiology Section Chief
Policy	Elizabeth Cuervo Tilson, MD, MPH
	State Health Director
	Chief Medical Officer
Vaccine Update	Ryan Jury, RN, MBA
	COVID-19 Vaccine Program Director
	ŭ
Contact Tracing	Erika Samoff, PHD, MPH
	Surveillance Manager NC DHHS
Testing	Natalie Ivanov, MPH
5	Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.
SLPH	Scott M. Shone, PhD, HCLD(ABB)
-	Laboratory Director
	, ,
Distribution of N95 Masks	Charlene Wong ,MD, MSHP David Ezzell
	Chief Health Policy Officer for COVID-19 at NC DHHS EMS Education Consultant
nfection Prevention Update	Emily Berns, MPH, RN
······································	Nurse Consultant: Division of Public Health, Communicable Disease Branch
	NC Department of Health and Human Services
Waste Water Surveillance	Ariel Christensen, MPH
	Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch
	Division of Public Health NC DHHS
The department of	
HUMAN SERVICES	QUESTIONS?
Please use the Zoom O	&A function or email your questions to: questionsCOVID19webinar@gmail.com

## **Infection Prevention Update**

Beth Lovette, RN, BSN, MPH Deputy Director/Section Chief Local and Community Support		
Local and Community Support		
Zack Moore, MD, MPH		
State Epidemiologist and Epidemiology Section Chief		
Elizabeth Cuervo Tilson, MD, MPH State Health Director		
State Health Director Chief Medical Officer		
Ryan Jury, RN, MBA		
COVID-19 Vaccine Program Director		
Erika Samoff, PHD, MPH		
Surveillance Manager NC DHHS		
Natalie Ivanov, MPH		
Director of DHHS State-wide COVID testing program and COVID vaccination vendor program.		
Scott M. Shone, PhD, HCLD(ABB)		
Laboratory Director		
Charlene Wong ,MD, MSHP David Ezzell		
Chief Health Policy Officer for COVID-19 at NC DHHS EMS Education Consultant		
Emily Berns, MPH, RN		
Nurse Consultant: Division of Public Health, Communicable Disease Branch		
NC Department of Health and Human Services		
Ariel Christensen, MPH		
Environmental Epidemiologist: Occupational and Environmental Epidemiology Branch		
Division of Public Health NC DHHS		
QUESTIONS?		
nction or email your questions to: questionsCOVID19webinar@gmail.com		

## Updated CDC Work Restriction Guidance for Healthcare Personnel

cdc.gov/coronavirus

### Work Restrictions for HCP With SARS-CoV-2 Infection and Exposures

HCP are considered "boosted" if they have received all COVID-19 vaccine doses, including a booster dose, as recommended by CDC. HCP are considered "vaccinated" or "unvaccinated" if they have NOT received all COVID-19 vaccine doses, including a booster dose, as recommended by CDC.

For more details, including recommendations for healthcare personnel who are immunocompromised, refer to Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 (conventional standards) and Strategies to Mitigate Healthcare Personnel Staffing Shortages (contingency and crisis standards).

#### Work Restrictions for HCP With SARS-CoV-2 Infection

Vaccination Status	Conventional	Contingency	Crisis
Boosted, Vaccinated, or Unvaccinated	10 days OR 7 days with negative test <sup>†</sup> , if asymptomatic or mildly symptomatic (with improving symptoms)	5 days with/without negative test, if asymptomatic or mildly symptomatic (with improving symptoms)	No work restriction, with prioritization considerations (e.g., asymptomatic or mildly symptomatic)

#### Work Restrictions for Asymptomatic HCP with Exposures


Vaccination Status	Conventional	Contingency	Crisis
Boosted	No work restrictions, with negative test on days 2 <sup>‡</sup> and 5–7	No work restrictions	No work restrictions
Vaccinated or Unvaccinated, even if within 90 days of prior infection	10 days OR 7 days with negative test	No work restriction with negative tests on days 1 <sup>‡</sup> , 2, 3, & 5–7	No work restrictions (test if possible)

#### †Negative test result within 48 hours before returning to work

\*For calculating day of test: 1) for those with infection consider day of symptom onset (or first positive test if asymptomatic) as day 0; 2) for those with exposure consider day of exposure as day 0



CS12866A | December 23, 2021 527 PM



- Vaccinated staff not yet eligible for booster fall into "boosted" row, unless staffing allows for work restriction
- Exposure definition now includes use of a facemask (instead of respirator) when the contact was unmasked
- Community guidance for shortened isolation/quarantine does not include LTC visitors or residents



https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html https://www.cdc.gov/coronavirus/2019-ncov/hcp/mitigating-staff-shortages.html

### Waste Water Surveillance

Opening Remarks & Leadership Update		Beth Lovette, RN, BSN, MPH Deputy Director/Section Chief	
		Local and Community Support	
Epi Picture		Zack Moore, MD, MPH	
		State Epidemiologist and Epidemiology Section Chief	
Policy		Elizabeth Cuervo Tilson, MD, MPH	
		State Health Director	
		Chief Medical Officer	
Vaccine Update		Ryan Jury, RN, MBA	
		COVID-19 Vaccine Program Director	
Contact Tracing		Erika Samoff, PHD, MPH	
-		Surveillance Manager NC DHHS	
Testing		Natalie Ivanov, MPH	
-		Director of DHHS State-wide COVID testing program and C	OVID vaccination vendor program.
SLPH		Scott M. Shone, PhD, HCLD(ABB)	
		Laboratory Director	
Distribution of N95 Masks		Charlene Wong ,MD, MSHP	David Ezzell
		Chief Health Policy Officer for COVID-19 at NC DHHS	EMS Education Consultant
Infection Prevention Updat	e	Emily Berns, MPH, RN	
		Nurse Consultant: Division of Public Health, Communicable Disease Branch	
		NC Department of Health and Human Services	
Waste Water Surveillance		Ariel Christensen, MPH	entel Enidemialemy Drawsk
		Environmental Epidemiologist: Occupational and Environme Division of Public Health NC DHHS	ental Epidemiology Branch
HEALTH AND HUMAN SERVICES		QUESTIONS?	
· · · · · · · · · · · · · · · · · · ·	Please use the Zoom Q&A function o	r email your questions to: questionsCOVID19webinar@gm	nail.com




# NC Wastewater Monitoring Network Update

# Ariel Christensen, MPH

## January 11, 2022


**Occupational and Environmental Epidemiology Branch North Carolina Department of Health and Human Services** 

## Wastewater levels are increasing in NC



https://covid19.ncdhhs.gov/dashboard/wastewater-monitoring

## New sites coming soon!



## **Next steps**

- Up to 20 new sites in North Carolina to start sampling wastewater for 12 months as part of CDCfunded commercial contract with <u>LuminaUltra</u> (early 2022)
- CDC adding wastewater data to the <u>COVID Data</u> <u>Tracker</u> in Jan 2022
- Building laboratory capacity with the NC State Lab of Public Health (training by UNC Institute of Marine Sciences)
- Incorporating screening and sequencing for variant detection

## Upcoming

Please take a moment to complete a survey Assessing the Role of Wastewater Data in Pandemic Management, for our partners at Mathematica – <u>https://www.surveymonkey.com/r/5TMMZ93</u> by January 16th. All counties welcome!

First statewide NC Wastewater Monitoring Network Year Annual Meeting on January 27<sup>th</sup> 10:30-11:30am. We will review progress thus far and next steps. All counties welcome!

## **Questions?**

### Ariel Christensen, MPH

### NCDHHS Occupational and Environmental Epidemiology Branch

ariel.Christensen@dhhs.nc.gov

https://covid19.ncdhhs.gov/dashboard/wa stewater-monitoring

Thanks also to Virginia Guidry, Steven Berkowitz (pictured with samples), Stacie Reckling, Alex Flynt, Rachel Noble, Tom Clerkin, Denene Blackwood, Rachelle Beattie, Chris Goforth, Emanuele Sozzi, and many other collaborators!

